Dr. John LaMattina Joins Ziarco as Strategic Advisor
Published: Mar 18, 2013
Commenting on his appointment, Dr LaMattina said: "Ziarco has amassed an excellent portfolio of early drug candidates with great potential. I am very much looking forward to working with the Ziarco team to convert these assets into valued new medicines."
Ziarco’s CEO, Dr Mike Yeadon, commented: "We are delighted that John is joining the team as a Strategic Advisor. Under his inspirational leadership during his long career at Pfizer, not only were several excellent medicines discovered and developed, but many of what are now industry-recognised R&D best-practises were established, as were many future leaders also. His expertise will be invaluable to use as we drive our portfolio of preclinical and clinical programs forward." John L. LaMattina, PhD
Dr. LaMattina is a Senior Partner at PureTech and was previously President, Pfizer Global Research and Development and Senior Vice President, Pfizer Inc.
During Dr. LaMattina’s leadership tenure Pfizer advanced a number of important new medicines including Chantix, Selzentry, Lyrica, Inlyta, Xalkori and Xaljenz. He is the author of numerous scientific publications and U.S. patents. In addition, Dr. LaMattina is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued & Distrusted – Can the pharma industry restore its broken image.” Dr. LaMattina serves on the Board of Directors of Ligand Pharmaceuticals, Vedanta and Gelesis, and is a member of the Scientific Advisory Board of Trevena Pharmaceuticals.
Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes a histamine H4 receptor antagonist programme with potential in multiple therapeutic areas, including asthma, allergic rhinitis, pruritus, skin diseases and pain. A lead H4 antagonist has completed a Phase 1 multiple ascending dose study. A second clinical-stage programme targets inflammatory disorders by inhibiting cytosolic phospholipase A2 (cPLA2). The pipeline is completed by a histamine H3 receptor antagonist programme possessing CNS-sparing properties which is in advanced preclinical development and an early-stage spleen tyrosine kinase (SYK) inhibitor programme suitable for topical administration. Investors in Ziarco include Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P. and Pfizer Venture Investments.